New 20-Strain pneumonia vaccine trial launches in china
NCT ID NCT07023081
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new vaccine that protects against 20 types of pneumococcal bacteria, which can cause pneumonia and other infections. Around 200 healthy Chinese adults, children, and infants will receive the vaccine to see if it is safe and how well it triggers an immune response. The vaccine is given in different doses depending on age, and participants are monitored for side effects over several months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
Nanning, Guangxi, 530021, China
-
Wuming District Center for Disease Control and Prevention
Chengxiang, Nanning, 530199, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New vaccine aims to shield kids from pneumonia and meningitis
- New vaccine aims to shield babies from pneumonia and meningitis
- New infant vaccine trial aims to shield against pneumonia and meningitis
- New vaccine trial aims to shield toddlers from pneumococcal disease
- New 21-Valent vaccine aims to shield HIV patients from pneumococcal disease
- Can a pneumonia vaccine protect the most vulnerable children?